Ascentage Pharma Group International (AAPG) Equity Average (2023 - 2025)
Ascentage Pharma Group International (AAPG) has disclosed Equity Average for 3 consecutive years, with $112.4 million as the latest value for Q4 2025.
- For Q4 2025, Equity Average rose 382.71% year-over-year to $112.4 million; the TTM value through Dec 2025 reached $112.4 million, up 382.71%, while the annual FY2025 figure was $94.7 million, 1789.79% up from the prior year.
- Equity Average hit $112.4 million in Q4 2025 for Ascentage Pharma Group International, up from $23.3 million in the prior quarter.
- Across five years, Equity Average topped out at $112.4 million in Q4 2025 and bottomed at $23.3 million in Q4 2024.
- Average Equity Average over 3 years is $56.5 million, with a median of $33.6 million recorded in 2023.
- Year-over-year, Equity Average crashed 30.74% in 2024 and then surged 382.71% in 2025.
- Ascentage Pharma Group International's Equity Average stood at $33.6 million in 2023, then tumbled by 30.74% to $23.3 million in 2024, then soared by 382.71% to $112.4 million in 2025.
- According to Business Quant data, Equity Average over the past three periods came in at $112.4 million, $23.3 million, and $33.6 million for Q4 2025, Q4 2024, and Q4 2023 respectively.